Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;88(2):471-473.
doi: 10.1016/j.jaad.2022.06.019. Epub 2022 Jun 16.

Predictors of severity in paradoxical psoriasis from biologic therapies: A systematic review

David O Croitoru  1 , Steph G Brooks  2 , Nikki Nathanielsz  2 , Orli Silverberg  2 , Ioana Nicolau  3 , Aaron M Drucker  4 , Mark Silverberg  5 , Jensen Yeung  6 , James J Limacher  7 , Vincent Piguet  8
Affiliations

Predictors of severity in paradoxical psoriasis from biologic therapies: A systematic review

David O Croitoru et al. J Am Acad Dermatol. 2023 Feb.
No abstract available

Keywords: biologic-induced psoriasis; paradoxical psoriasis; psoriasiform reactions; risk and etiology; severity; systematic review.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Piguet has no personal financial ties with any pharmaceutical company. He undertakes advisory work for Pfizer, AbbVie, Janssen, UCB, Novartis, Almirall, and Celgene. He has received honoraria from Kyowa Kirin Co, Ltd. In his role as Department Division Director of Dermatology at the University of Toronto, Dr Piguet has received departmental support from AbbVie, Bausch Health, Celgene, Janssen, LEO Pharma, Lilly, NAOS, Novartis, Pfizer, Pierre-Fabre, and Sanofi in the past 36 months. Dr Drucker has received compensation from the British Journal of Dermatology (reviewer and Section Editor), the American Academy of Dermatology (guidelines writer), and the National Eczema Association (grant reviewer). He has been a paid consultant for the Canadian Agency for Drugs and Technology in Health (Federal Agency). Dr Yeung has been a speaker, consultant, and investigator for AbbVie, Allergan, Amgen, Astellas, Boehringer Ingelheim, Celgene, Centocor, Coherus, Dermira, Eli Lilly, Forward, Galderma, GlaxoSmithKline, Janssen, Leo, Medimmune, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Takeda, UCB, Valeant, and Xenon. Authors Croitoru, Brooks, Nathanielsz, O Silverberg, Nicolau, M Silverberg, and Limacher have no conflicts of interest to declare.

Publication types